Related content

Comment on “Analysis of Longitudinal Trials With Protocol Deviations: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation,” by Carpenter, Roger, and Kenward

By      

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 6, 2014-11 ,pp. : 1358-1362

Taylor & Francis Ltd

Access to resources Recommend Favorite

Response to Mousavizadeh et al.: Oxidative toxicity and glutamate excitotoxicity in multiple sclerosis

By Neuhaus O.   Kieseier B.C.   Archelos J.J.   Hartung H.-P.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 11, 2003-11 ,pp. : 564-565

Elsevier

Access to resources Recommend Favorite

Defining, Evaluating, and Removing Bias Induced by Linear Imputation in Longitudinal Clinical Trials with MNAR Missing Data

By Helms Ronald  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 2, 2011-03 ,pp. : 226-251

Taylor & Francis Ltd

Access to resources Recommend Favorite

Response to Letter to the Editor: Validation Testing in Thorough QT/QTc Clinical Trials by Yi Tsong et al.

By Tsong Yi   Zhong Jinglin   Chen Wen Jen  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 3, 2010-05 ,pp. : 688-688

Taylor & Francis Ltd

Access to resources Recommend Favorite

Response to Comments on “No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”

By Hawkins Neil   Scott David A.   Thatcher Nicholas  

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 683-683

Blackwell Publishing

Access to resources Recommend Favorite